Skip to main content
NCBI home page
Molecules logoLink to Molecules
. 2024 Jan 17;29(2):464. doi: 10.3390/molecules29020464

A Facile Ugi/Ullmann Cascade Reaction to Access Fused Indazolo-Quinoxaline Derivatives with Potent Anticancer Activity

Yong Li 1,2, Liujun He 1, Hongxia Qin 1,*, Yao Liu 1, Binxin Yang 1, Zhigang Xu 1, Donglin Yang 1,*
Editors: Antonio Palumbo Piccionello, Yong You, Zhen Hua Wang
PMCID: PMC10820152  PMID: 38257377

Abstract

A facile methodology for the construction of a complex heterocycle indazolo-fused quinoxalinone has been developed via an Ugi four-component reaction (U-4CR) followed by an intramolecular Ullmann reaction. The expeditious process features an operationally simple approach, time efficiency, and a broad substrate scope. Biological activity was evaluated and demonstrated that compound 6e inhibits human colon cancer cell HCT116 proliferation with an IC50 of 2.1 μM, suggesting potential applications for developing a drug lead in medicinal chemistry.

Keywords: heterocycles, multicomponent reactions (MCRs), organic synthesis, indazolo-fused quinoxalinone, anticancer activity

1. Introduction

Fused nitrogen polycyclic aromatic systems are one of the privileged core skeletons that are of great significance in biochemistry and the pharmaceutical industry [1,2,3,4]. Indazole and quinoxalinone cores, as two of them, are not only key scaffolds of many natural products but also essential units of a number of synthetic compounds possessing a wide spectrum of pharmaceutical activities [5,6,7,8,9,10,11,12,13,14,15]. In addition, indazole-fused polycyclic conjugated skeletons have received considerable interest as they are frequently encountered in natural products, biologically active compounds, and fluorescent probes (Figure 1) [16,17,18,19,20,21].

Figure 1.

Figure 1

Open in a new tab

Natural product, bioactive, and drug molecules containing indazole structure.

Despite their importance, reliable methods for the synthesis of indazole-related polyheterocycles (PHCs) are rather limited [22,23,24,25], and some of them still suffer from the use of highly functionalized substrates, the production of a large amount of waste, and low atom economy. In recent years, isocyanide-based multicomponent reactions have been reported for the construction of indazole-related polyheterocycles with a facile and efficient process. For example, Jeong and coworkers reported the synthesis of novel 2-aryl-5H-imidazo [1,2-b]indazol-3-amine derivatives by using the Groebke–Blackburn–Bienaymé (GBB) reaction, which involved the reagents of 3-amino-1H indazoles, aldehydes, and isonitriles (Scheme 1a) [26]. Then, the same team reported the synthesis of novel amino-indazolo[3′,2′:2,3]imidazo[1,5-c]quinazolin-6(5H)-ones via a sequential post-GBB cyclization/spiro ring expansion triggered by a [1,5]-hydride shift (Scheme 1b) [27]. Our group has also reported the synthesis of pyrazole-pyrazines using a catalyst-free post-Ugi cascade reaction (Scheme 1c) [28]. In spite of this, more efficient synthesis methods for the construction of complex polyheterocycles are still desired.

Scheme 1.

Scheme 1

Open in a new tab

Strategies for the synthesis of indazolo-fused polycyclics via isocyanide-based multicomponent reactions.

As an evergreen in organic chemistry, multicomponent reactions (MCRs) never became old-fashioned or tedious [29,30,31,32,33], because they always inspire creative spirits by following the fundamental quest: more than two compounds are reacted in a one-pot fashion to form two or more bonds. The post-Ugi reactions [34,35,36,37], as typical MCRs, are well suited for the construction of important heterocycles, macrocycles, polymers, and other compounds in drug discovery and natural product synthesis [38,39,40,41,42,43]. In the course of our continued study on the construction of novel N-fused heterocyclic chemical spaces and activity evaluation from Ugi adductive [28,36,44,45,46], we hoped to establish a highly efficient diversity-oriented synthetic route to indazole-fused polycyclics utilizing a sequential one-pot Ugi/Ullmann reaction, as shown in Scheme 1d. We reasoned that the Ugi product involving 3-carboxyindazole and 2-bromoaniline would undergo an intramolecular Ullmann cyclization cascade process to yield the indazolo-quinoxaline derivatives. As excepted, indazolo-quinoxaline derivatives were synthesized by a facile and efficient process and are discussed below.

2. Results and Discussion

The starting materials, 3-carboxyindazole 1a, 4-chlorobenzaldehyde 2a, 2-bromoaniline 3, and tert-butyl isocyanide 4a, were mixed in methanol at room temperature and under air to afford the desired Ugi product 5a. With compound 5a in hand, we proceeded to optimize the conditions for the subsequent Ullmann reaction, and the results are shown in Table 1. Compound 5a was treated in N,N-dimethylformamide (DMF) with different bases under a variety of microwave irradiation conditions. When an inorganic base was used, the target compound 6a was observed in a relatively low yield (55%) (Table 1, entry 1–5). The results of these screening experiments revealed that when organic bases 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 4-dimethylaminopyridine (DMAP), and triethylamine) (TEA) were used, target compound 6a was observed in the LC/MS spectrum with very low yield (Table 1, entries 6–8). Addition of a copper catalyst and ligand resulted in a considerable increase in the yield (Table 1, entries 9–17). Different ligands were screened by performing the reaction with K2CO3 and CuI (Table 1, entries 9–14), and the results showed that when tetramethylethylenediamine (TMEDA) was used as the ligand, compound 6 was obtained with a high yield (95%). When we carried out the reaction using another copper catalyst, such as CuBr, Cu2O, and Cu(OTf)2, in the presence of TMEDA, we only achieved yields of 49–65% (entries 15–17). The results proved that the optimal conditions for the Ullmann reaction were K2CO3 as the base in the presence of CuI and TMEDA in DMF under microwave at 150 °C for 30 min. After the Ullmann reaction conditions were optimized, we continued to investigate the possibility of carrying out this reaction as a one-pot procedure.

Table 1.

Optimization of the Ullmann reaction conditions from 5a a.

graphic file with name molecules-29-00464-i001.jpg
Entry Base
(2.0 Eqiv.)		 Cat.
(10 mol%)		 Ligand
(20 mol%)		 Temp.
(°C)		 Time
(Min)		 Yield of 6a (%) b
1 K2CO3 / / MW 120 10 min Trace
2 K2CO3 / / MW 150 10 min 25
3 K2CO3 / / MW 150 30 min 55
4 KOtBu / / MW 150 30 min 31
5 Cs2CO3 / / MW 150 30 min 43
6 TEA / / MW 150 30 min Trace
7 DBU / / MW 150 30 min 15
8 DMAP / / MW 150 30 min 17
9 K2CO3 CuI L1 MW 150 30 min 57
10 K2CO3 CuI L2 MW 150 30 min 67
11 K2CO3 CuI L3 MW 150 30 min 79
12 K2CO3 CuI L4 MW 150 30 min 95
13 K2CO3 CuI L5 MW 150 30 min 83
14 K2CO3 CuI L6 MW 150 30 min 73
15 K2CO3 CuBr L4 MW 150 30 min 65
16 K2CO3 Cu2O L4 MW 150 30 min 53
17 K2CO3 Cu(OTf)2 L4 MW 150 30 min 49
Open in a new tab

a Reaction conditions: 5a (0.1 mmol) and base (0.2 mmol) in DMF (1.0 mL) under air. b Isolated yields. MW = microwave irradiation.

With the optimized intramolecular Ullmann cyclization reaction conditions in hand, we investigated the cyclization reaction with the unpurified Ugi product 5a. In all cases, the initial Ugi products were used directly in the next step without further purification after the removal of the solvent. In one pot, the cascade reaction produced the final product 6a with a 73% yield for two steps, which showed no discernible impact on the overall yield. We then investigated the scope of this one-pot procedure by varying the starting materials (in Scheme 2). First, different aldehydes were tested. The results showed that different substituents on the aryl aldehydes exhibited good performance, affording compounds 6a–6e with 62–78% yield, and the electronic properties of the substituent did not impact the reactivity. Strikingly, when heterocyclic aldehydes and aliphatic aldehydes were used as input in the Ugi reaction, compounds 6f and 6g were also obtained, with 53% and 62% yields, respectively. Next, different isocyanides were used as Ugi inputs, and the results showed that the corresponding indazolo-quinoxalines 6i–6h were generated smoothly with a 56–76% yield. The substituents of the benzene of aniline were also investigated for obtaining compounds 6m–6q. Further investigations of the substituents on carboxyindazole revealed that different substituents didn’t make a significant difference in the reaction yield. The Cl- or Me-substituted carboxyindazoles were involved in the protocol, and the products 6r–6u were obtained in 76–85% yields. It is worth noting that when formaldehyde was used, the product 6v was obtained with a 77% yield. All the results showed that a variety of different starting materials were successfully employed under the optimized conditions for the construction of structurally diverse indazolo-quinoxalines 6a–6v, with yields in the range of 53–78% (Scheme 2), indicating a good functional group tolerance.

Scheme 2.

Scheme 2

Open in a new tab

Scope of the Ugi/Ullmann reaction route leading to indazolo-quinoxaline derivatives 6a–6v a. a Reaction conditions: 1 (1.0 mmol), 2 (1.0 mmol), 3 (1.0 mmol), and 4 (1.0 mmol) in MeOH (2.0 mL) under air. After the solvent removed, added K2CO3 (2.0 mmol), CuI (0.1 mmol), and TMEDA (0.2 mmol) in DMF (5.0 mL) under microwave irradiation at 150 °C for 30 min. Overall yield of isolated product.

To extend the application of the synthesized compound in medical chemistry for developing a drug lead from compounds 6, the antiproliferative effect of compounds 6 was evaluated in several human cancer cell lines. To our delight, a significant cell growth inhibitory effect was observed, especially compound 6e, which exhibited better anticancer activities in the human colorectal cancer HCT116 cell lines than other cell lines (Figure 2). It is worth noting that compounds 6e, 6h, and 6i showed excellent anticancer activities, with IC50 of 2.1 μM, 2.7 μM, and 2.8 μM, respectively (Figure 3), which is comparable to 36.80 for etoposide, as reported in our previous work [44]. Further efforts are ongoing to explore the mechanism of action of drug leads and optimize their potency and drug properties.

Figure 2.

Figure 2

Open in a new tab

Anticancer activities of compounds 6a–v against different cancer cell lines. All MTT assays were repeated three times using six samples per assay. Proliferation inhibition activity of compounds 6a–v was assessed by MTT in breast cancer cells (MDA-MB-453), liver cancer cells (Hep3B), and colon cells (HCT116). These cells were treated with compounds 6 at 10 μM for 48 h, respectively, then cell viability was measured.

Figure 3.

Figure 3

Open in a new tab

The half-maximal inhibitory concentration (IC50) of compound 6e, 6h, and 6i was determined in HCT116, MDA-MB-453, and Hep3B cell lines.

3. Materials and Methods

3.1. General Information

1H and 13C NMR data were recorded on a Bruker (Billerica, MA, USA) 400 spectrometer. 1H NMR data are reported as follows: chemical shift in ppm (δ), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant (Hz), relative intensity. 13C NMR data are reported as follows: chemical shift in ppm (δ). HPLC-MS analyses were performed on a Shimadzu-2020 LC-MS instrument (Kyoto City, Japan) using the following conditions: Shim-pack VPODS C18 column (reverse phase, 150 × 2.0 mm); 80% acetonitrile and 20% water over 6.0 min; flow rate of 0.4 mL/min; UV photodiode array detection from 200 to 300 nm. The products were purified using Biotage (Uppsala, Sweden) Isolera™ Spektra Systems and hexane/EtOAc solvent systems. Unless otherwise specified, all chemicals were purchased from commercial sources and used without further treatment. All microwave irradiation experiments were carried out according to our previous report [44,45].

3.2. Cell Lines and Culture

The human tumor cells Hep3B, HCT116, and MDA-MB-453 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Hep3B cells were cultured with MEM (Pricella, PM150410, Wuhan, China) and supplemented with 10% fetal bovine serum (FBS, Gibco, 10100147, Waltham, MA, USA, Australian origin) and 1 mM sodium pyruvate (NaP). HCT116 cells were cultured in McCoy’s 5a medium (Gibco, 16600108, Waltham, MA, USA) supplemented with 10% FBS. MDA-MB-453 cells were cultured with high-glucose DMEM medium (Hyclone, SH30022.01, Logan, UT, USA) with 10% FBS added. All used cells were incubated in an incubator at 37 °C and 5% CO2 in a humidified atmosphere.

3.3. Cell Viability Assay

The cell viability and the IC50 value of compounds 6a–v in the human tumor cells were evaluated using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT, Beyotime, ST316, Shanghai, China) assay. Briefly, the tumor cells were harvested, counted, and seeded into the 96-well plate, with a density of 2 × 103 cells per well. After incubation for 24 h, 100 µL of medium with 20 µM compounds were added and incubated for 2 days for the initial screening. To assess anticancer activity, 20 μL of MTT solution (5 mg/mL in PBS) were added to each well and incubated for another 4 h. Then, the medium was removed, and 200 μL of DMSO was added to each well to dissolve the formazan cystals. The absorbance was measured at 570 nm using a microplate reader (Bio-Tek, Winooski, VT, USA). The experiments were repeated three times, and growth inhibition curves and IC50 values were generated using GraphPad Prism 8.0.

3.4. General Procedure for Synthesis of Compounds 6a–v

Aldehyde (1.0 mmol, 1.0 eq.), MeOH (2 mL), and amine (1.0 mmol, 1.0 eq.) were sequentially added to a 10 mL microwave vial and stirred for 10 min. under air. Then, carboxylic acid (1.0 mmol, 1.0 eq.) and isocyanide (1.0 mmol, 1.0 eq.) were added separately. The mixture was stirred for 6–12 h at room temperature and monitored with TLC. When no isocyanide was present, the solvent was removed using rotary evaporation. The residue was dissolved in DMF (5 mL) in a 10 mL microwave vial, then, K2CO3 (2.0 eq.), CuI (20 mol%), and TMEDA (20 mol%) were added. The vial was sealed and heated in a microwave at 150 °C for 30 min. The solvent was removed using rotary evaporation after the reaction was completed. The residue was dissolved in EtOAc (15 mL) and washed with brine. The EtOAc phase was dried over anhydrous Na2SO4 and concentrated. The residue was purified using silica gel column chromatography using a gradient of EtOAc/hexane (0–100%) to afford the relative product 6.

N-(tert-butyl)-2-(4-chlorophenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6a), purified by flash chromatography using a gradient of EtOAc/hexane (0–40%), white solid, 289 mg, yield 62%. 1H NMR (400 MHz, CDCl3) δ 8.68 (dd, J = 7.8, 1.8 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H), 7.61–7.49 (m, 2H), 7.47–7.36 (m, 3H), 7.32 (q, J = 8.9 Hz, 4H), 6.98 (s, 1H), 5.99 (s, 1H), 1.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.50, 155.64, 149.05, 134.04, 132.56, 129.35, 129.27, 128.94, 128.30, 128.20, 125.23, 125.16, 124.51, 122.70, 121.85, 121.00, 118.47, 117.84, 117.73, 59.10, 52.24, 28.56. HRMS (ESI) m/z calcd. for C26H24ClN4O2+ (M + H)+ 459.1582, found 459.1580.

N-(tert-butyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6b), 1H NMR (400 MHz, CDCl3) δ 8.66 (dd, J = 7.8, 1.9 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.60–7.51 (m, 2H), 7.46–7.27 (m, 8H), 6.94 (s, 1H), 6.02 (s, 1H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.70, 155.70, 149.15, 134.16, 129.87, 128.97, 128.27, 128.09, 127.83, 125.17, 125.09, 124.28, 123.04, 121.94, 121.35 118.35, 117.79, 117.65, 60.54, 52.12, 28.57. HRMS (ESI) m/z calcd. for C26H25N4O2+ (M + H)+ 425.1972, found 425.1974.

N-(tert-butyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-(p-tolyl)acetamide (6c), 1H NMR (400 MHz, CDCl3) δ 8.66 (d, J = 9.7 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.03–7.93 (m, 1H), 7.60–7.51 (m, 2H), 7.45–7.33 (m, 3H), 7.27–7.19 (m, 3H), 7.13 (d, J = 7.1 Hz, 1H), 6.85 (s, 1H), 5.98 (s, 1H), 2.31 (s, 3H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.74, 155.69, 149.16, 138.87, 134.16, 130.02, 129.15, 128.88, 128.44, 128.09, 125.17, 125.05, 124.86, 124.22, 123.13, 121.94, 121.42, 118.26, 117.77, 60.81, 52.08, 28.58, 21.58. HRMS (ESI) m/z calcd. for C27H27N4O2+ (M + H)+ 439.2129, found 439.2129.

2-(4-Bromophenyl)-N-(tert-butyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6d), 1H NMR (400 MHz, CDCl3) δ 8.67 (dd, J = 8.0, 1.7 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.60–7.50 (m, 2H), 7.49–7.34 (m, 5H), 7.28 (s, 1H), 7.26 (s, 1H), 6.97 (s, 1H), 6.03 (s, 1H), 1.32 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.33, 155.64, 149.18, 132.99, 131.92, 129.54, 129.33, 128.39, 128.25, 125.33, 125.20, 124.56, 122.79, 122.24, 121.99, 121.22, 118.39, 117.89, 117.78, 59.19, 52.24, 28.56. HRMS (ESI) m/z calcd. for C26H24BrN4O2+ (M + H)+ 503.1077, found 503.1075.

N-(tert-butyl)-2-(4-methoxyphenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6e), 1H NMR (400 MHz, CDCl3) δ 8.68–8.59 (m, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.62–7.49 (m, 2H), 7.44–7.32 (m, 5H), 6.88 (d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 5.96 (s, 1H), 3.78 (s, 3H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.99, 159.43, 155.65, 149.13, 129.98, 129.36, 128.24, 128.08, 126.10, 125.17, 125.01, 124.19, 123.13, 121.90, 121.39, 118.10, 117.75, 117.66, 114.39, 60.37, 55.31, 52.05, 28.59. HRMS (ESI) m/z calcd. for C27H27N4O3+ (M + H)+ 455.2078, found 455.2086.

N-(tert-butyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-(thiophen-2-yl)acetamide (6f) 1H NMR (400 MHz, CDCl3) δ 8.69–8.62 (m, 1H), 8.39 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.56 (ddd, J = 8.8, 4.9, 1.6 Hz, 2H), 7.46–7.37 (m, 3H), 7.32 (dd, J = 5.1, 1.1 Hz, 1H), 7.09 (d, J = 3.0 Hz, 1H), 6.94 (dd, J = 5.1, 3.7 Hz, 1H), 5.95 (s, 1H), 5.29 (s, 1H),1.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.23, 155.20, 149.14, 135.75, 128.34, 128.09, 127.38, 126.49, 125.26, 124.44, 122.00, 121.28, 117.85, 53.45, 52.25, 28.52. HRMS (ESI) m/z calcd. for C24H23N4O2S+ (M + H)+ 431.1536, found 431.1539.

N-(tert-butyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-4-phenylbutanamide (6g), 1H NMR (400 MHz, CDCl3) δ 8.58 (dd, J = 8.1, 1.3 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.58–7.52 (m, 1H), 7.51–7.46 (m, 1H), 7.45–7.36 (m, 2H), 6.94 (s, 5H), 6.27 (s, 1H), 5.87 (s, 1H), 2.80 (ddd, J = 21.6, 13.4, 7.2 Hz, 2H), 2.48 (dd, J = 11.1, 6.1 Hz, 2H), 1.28 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 168.93, 155.94, 149.01, 140.11, 128.29, 128.02, 127.99, 125.83, 125.22, 125.16, 124.42, 121.79, 121.04, 117.94, 117.80, 55.21, 51.82, 33.01, 28.55. HRMS (ESI) m/z calcd. for C28H29N4O2+ (M + H)+ 453.2285, found 453.2286.

2-(4-Chlorophenyl)-N-(2,6-dimethylphenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6h), 1H NMR (400 MHz, CDCl3) δ 8.67 (d, J = 8.0 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.68–7.52 (m, 3H), 7.49 (d, J = 8.4 Hz, 2H), 7.40 (ddd, J = 20.5, 10.5, 7.2 Hz, 5H), 7.22 (s, 1H), 7.04 (dt, J = 17.4, 6.6 Hz, 3H), 2.13 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 165.72, 155.76, 149.19, 135.16, 134.41, 133.05, 132.14, 129.31, 128.47, 128.34, 127.64, 125.46, 125.31, 124.78, 122.69, 121.99, 121.13, 118.24, 117.96, 58.84, 18.47. HRMS (ESI) m/z calcd. for C30H24ClN4O2+ (M + H)+ 507.1582, found 507.1572.

2-(4-Chlorophenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (6i), 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 7.6 Hz, 1H), 8.34 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 15.5, 7.6 Hz, 2H), 7.36 (ddd, J = 26.0, 16.2, 8.0 Hz, 7H), 6.97 (s, 1H), 6.11 (s, 1H), 1.64 (q, J = 15.0 Hz, 2H), 1.39 (d, J = 13.2 Hz, 6H), 0.80 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 165.98, 155.55, 149.14, 134.04, 132.33, 129.36, 128.91, 128.36, 128.29, 125.28, 125.16, 124.56, 122.71, 121.93, 121.19, 118.37, 117.89, 117.77, 59.13, 56.19, 52.45, 31.50, 31.20, 28.85, 28.32. HRMS (ESI) m/z calcd. for C30H32ClN4O2+ (M + H)+ 515.2208, found 515.2210.

N-benzyl-2-(4-chlorophenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6j) 1H NMR (400 MHz, CDCl3) δ 8.57 (dd, J = 7.9, 1.8 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.55–7.45 (m, 2H), 7.41–7.31 (m, 4H), 7.31–7.26 (m, 3H), 7.21–7.11 (m, 5H), 7.04 (s, 1H), 6.84 (t, J = 5.3 Hz, 1H), 4.55–4.42 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 167.28, 155.65, 149.01, 137.50, 134.25, 132.08, 129.34, 129.18, 129.04, 128.61, 128.33, 127.72, 127.53, 125.32, 125.22, 124.58, 122.59, 121.79, 120.88, 118.13, 117.84, 117.80, 58.38, 44.08. HRMS (ESI) m/z calcd. for C29H22ClN4O2+ (M + H)+ 493.1426, found 493.1419.

2-(4-Chlorophenyl)-N-cyclohexyl-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6k), 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.57–7.48 (m, 2H), 7.42–7.25 (m, 7H), 7.03 (s, 1H), 6.36 (d, J = 7.6 Hz, 1H), 3.91–3.73 (m, 1H), 1.95 (d, J = 10.6 Hz, 1H), 1.72 (d, J = 11.9 Hz, 1H), 1.59 (dd, J = 35.6, 7.8 Hz, 3H), 1.38–1.20 (m, 2H), 1.19–1.09 (m, 1H), 1.01 (ddd, J = 14.9, 14.3, 4.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 166.32, 155.60, 149.03, 134.10, 132.40, 129.30, 128.96, 128.32, 128.25, 125.25, 125.16, 124.53, 122.67, 121.80, 121.00, 118.29, 117.84, 117.75, 58.58, 49.16, 32.69, 32.60, 25.34, 24.82, 24.75. HRMS (ESI) m/z calcd. for C28H26ClN4O2+ (M + H)+ 485.1739, found 485.1725.

N-butyl-2-(4-chlorophenyl)-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6l), 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 7.2 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.51 (dd, J = 14.9, 7.5 Hz, 2H), 7.40–7.26 (m, 7H), 7.01 (s, 1H), 6.57 (s, 1H), 3.23 (dd, J = 13.3, 6.6 Hz, 2H), 1.46–1.35 (m, 2H), 1.28–1.13 (m, 2H), 0.80 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 167.23, 155.63, 148.99, 134.13, 132.30, 129.33, 128.97, 128.32, 125.25, 125.16, 124.53, 122.62, 121.73, 120.88, 118.19, 117.84, 117.74, 58.45, 39.88, 31.27, 19.99, 13.66. HRMS (ESI) m/z calcd. for C26H24ClN4O2+ (M + H)+ 459.1582, found 459.1571.

N-(tert-butyl)-2-(2-chloro-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-(4-chlorophenyl)acetamide (6m), 1H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 2.1 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.59–7.53 (m, 1H), 7.50 (d, J = 9.1 Hz, 1H), 7.44–7.38 (m, 1H), 7.34–7.25 (m, 5H), 7.02 (s, 1H), 6.15 (s, 1H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.21, 155.40, 149.31, 134.25, 132.27, 130.30, 129.11, 129.08, 128.71, 128.12, 127.80, 125.78, 125.64, 122.76, 122.01, 121.11, 120.06, 117.97, 117.57, 58.86, 52.37, 28.59. HRMS (ESI) m/z calcd. for C26H23Cl2N4O2+ (M + H)+ 493.1193, found 493.1186.

2-(2-Bromo-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-N-(tert-butyl)-2-(4-chlorophenyl)acetamide (6n), 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 1.2 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.55–7.49 (m, 1H), 7.44 (dd, J = 13.4, 5.2 Hz, 2H), 7.38–7.25 (m, 5H), 7.04 (s, 1H), 6.32 (s, 1H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.24, 155.39, 149.20, 136.73, 134.23, 132.33, 130.94, 129.09, 128.66, 128.27, 125.93, 125.59, 122.67, 121.90, 120.94, 120.42, 120.34, 117.92, 117.52, 87.50, 58.84, 52.38, 28.60. HRMS (ESI) m/z calcd. for C26H23BrClN4O2+ (M + H)+ 537.0687, found 537.0678.

2-(3-Bromo-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-N-(tert-butyl)-2-(4-chlorophenyl)acetamide (6o), 1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.67 (s, 1H), 7.59–7.54 (m, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.46–7.41 (m, 1H), 7.37 (s, 4H), 6.83 (s, 1H), 5.91 (s, 1H), 1.37 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 165.82, 155.33, 149.24, 134.62, 132.27, 130.59, 129.37, 128.59, 127.47, 125.54, 124.17, 122.68, 122.06, 121.78, 121.19, 120.76, 119.04, 117.88, 59.96, 52.38, 28.55. HRMS (ESI) m/z calcd. for C26H23BrClN4O2+ (M + H)+ 537.0687, found 537.0685.

N-(tert-butyl)-2-(2-methyl-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6p), 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 1.0 Hz, 1H), 8.36 (dd, J = 8.4, 0.9 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.58–7.50 (m, 1H), 7.46–7.38 (m, 4H), 7.38–7.27 (m, 3H), 7.15 (dd, J = 8.7, 1.5 Hz, 1H), 6.97 (s, 1H), 6.06 (s, 1H), 2.47 (s, 3H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.78, 155.60, 149.10, 134.61, 134.25, 129.13, 128.90, 128.24, 128.17, 127.81, 127.56, 124.97, 124.93, 123.10, 121.91, 121.37, 118.32, 117.68, 117.55, 60.21, 52.09, 28.59, 20.82. HRMS (ESI) m/z calcd. for C27H27N4O2+ (M + H)+ 439.2129, found 439.2127.

N-(tert-butyl)-2-(3-chloro-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6q), 1H NMR (400 MHz, CDCl3) δ 8.58 (dd, J = 8.8, 1.2 Hz, 1H), 8.37 (dd, J = 8.4, 1.1 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.60–7.50 (m, 2H), 7.46–7.31 (m, 7H), 6.81 (s, 1H), 5.91 (s, 1H), 1.38 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.15, 155.49, 149.23, 133.93, 133.91, 130.96, 129.33, 128.73, 128.47, 127.95, 125.33, 124.37, 123.78, 122.84, 122.02, 121.32, 118.77, 118.04, 117.80, 61.13, 52.26, 28.55. HRMS (ESI) m/z calcd. for C26H24ClN4O2+ (M + H)+ 459.1582, found 459.1557.

N-(tert-butyl)-2-(9-chloro-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6r), 1H NMR (400 MHz, CDCl3) δ 8.55 (dd, J = 6.2, 3.5 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.90–7.84 (m, 1H), 7.56 (dd, J = 6.2, 3.4 Hz, 1H), 7.45–7.29 (m, 7H), 7.25 (dd, J = 5.1, 1.8 Hz, 1H), 6.92 (s, 1H), 6.19 (s, 1H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.59, 155.42, 149.22, 134.17, 134.13, 129.94, 129.06, 128.42, 128.32, 127.88, 126.28, 124.92, 124.39, 123.33, 122.39, 120.13, 118.40, 117.66, 116.85, 60.78, 52.17, 28.58. HRMS (ESI) m/z calcd. for C26H24ClN4O2+ (M + H)+ 459.1582, found 459.1583.

N-(tert-butyl)-2-(9-chloro-2-methyl-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6s), 1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 1.1 Hz, 1H), 7.45–7.31 (m, 7H), 7.21 (d, J = 8.4 Hz, 1H), 6.80 (s, 1H), 5.94 (s, 1H), 2.37 (s, 3H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.54, 155.44, 149.21, 139.05, 134.13, 134.04, 130.03, 129.08, 128.46, 127.95, 126.17, 125.50, 123.14, 122.92, 122.52, 120.21, 118.00, 117.57, 116.77, 61.16, 52.11, 28.53, 21.81. HRMS (ESI) m/z calcd. for C27H26ClN4O2+ (M + H)+ 473.1739, found 473.1733.

N-benzyl-2-(3-bromophenyl)-2-(9-chloro-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6t), 1H NMR (400 MHz, CDCl3) δ 8.56–8.48 (m, 1H), 7.90–7.82 (m, 2H), 7.57 (s, 1H), 7.51–7.42 (m, 2H), 7.41–7.35 (m, 2H), 7.24 (s, 1H), 7.20–7.09 (m, 7H), 6.99 (s, 2H), 4.54–4.41 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 166.89, 155.38, 149.12, 137.42, 135.73, 134.29, 131.59, 130.97, 130.38, 129.17, 128.66, 128.59, 127.73, 127.55, 126.57, 126.38, 125.01, 124.81, 123.05, 122.83, 121.83, 119.97, 118.22, 117.88, 116.96, 58.45, 44.13. HRMS (ESI) m/z calcd. for C29H21BrClN4O2+ (M + H)+ 571.0531, found 571.0534.

N-(tert-butyl)-2-(8-methyl-6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)-2-phenylacetamide (6u), 1H NMR (400 MHz, CDCl3) δ 8.62 (dd, J = 7.9, 1.6 Hz, 1H), 8.14 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.55 (dd, J = 8.0, 1.2 Hz, 1H), 7.37 (ddt, J = 18.2, 10.2, 7.2 Hz, 8H), 6.91 (s, 1H), 6.02 (s, 1H), 2.54 (s, 3H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 166.79, 155.85, 148.07, 135.20, 134.22, 131.12, 129.75, 128.93, 128.22, 127.87, 127.83, 125.32, 124.22, 122.33, 122.25, 119.64, 118.29, 117.48, 117.43, 60.51, 52.08, 28.58, 22.00. HRMS (ESI) m/z calcd. for C27H27N4O2+ (M + H)+ 439.2129, found 439.2119.

N-benzyl-2-(6-oxoindazolo[2,3-a]quinoxalin-5(6H)-yl)acetamide (6v), 1H NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.58 (d, J = 7.3 Hz, 1H), 8.27 (d, J = 7.5 Hz, 1H), 8.00 (d, J = 7.9 Hz, 1H), 7.71–7.40 (m, 5H), 7.38–7.14 (m, 5H), 5.10 (s, 2H), 4.31 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 167.08, 154.93, 148.74, 139.52, 131.13, 129.47, 128.73, 127.56, 127.30, 125.24, 124.66, 124.45, 123.68, 121.21, 121.18, 118.05, 117.43, 116.72, 44.74, 42.62. HRMS (ESI) m/z calcd. for C23H19N4O2+ (M + H)+ 383.1503, found 383.1487.

4. Conclusions

In summary, we developed a facile and efficient methodology for the construction of an indazole-fused polyheterocycle using a unique Ugi/Ullmann cascade reaction strategy. With this protocol, complex functionalized indazolo-quinoxaline derivatives were obtained in good to excellent yields in one pot, with excellent functional group tolerance. Anticancer activity evaluation revealed that the synthesized new compounds show potential anticancer activities that may have a wide range of applications in organic synthesis and medicinal chemistry.

Acknowledgments

The authors would like to thank H.Z. Liu and J. Xu for obtaining the LC/MS and HRMS data.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29020464/s1, X-ray of 6k; copies of 1H, 13C NMR spectra of compounds 6.

Click here for additional data file. (2.4MB, zip)

Author Contributions

Conceptualization, Y.L. (Yong Li), H.Q. and D.Y.; methodology, Y.L. (Yong Li), L.H., Y.L. (Yao Liu) and B.Y.; investigation, D.Y. and Z.X.; writing—original draft preparation, Y.L. (Yong Li) and H.Q.; writing—review and editing, Z.X. and D.Y.; supervision, Z.X. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All the required data are reported in the manuscript and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Statement

This research was funded by the Science and Technology Research Program of Chongqing Municipal Education Commission (KJQN202201330), the Natural Science Foundation of Chongqing Science and Technology Bureau (CSTB2022NSCQ-MSX0868 and CSTB2022NSCQ-MSX0236), and the Scientific Research Foundation of the Chongqing University of Arts and Sciences (P2019XY01).

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Flick A.C., Ding H.X., Leverett C.A., Kyne R.E., Jr., Liu K.K.C., Fink S.J., O’Donnell C.J. Synthetic Approaches to the New Drugs Approved during 2015. J. Med. Chem. 2017;60:6480–6515. doi: 10.1021/acs.jmedchem.7b00010. [DOI] [PubMed] [Google Scholar]
  • 2.Zhang L., Peng X.-M., Damu G.L.V., Geng R.-X., Zhou C.-H. Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry. Med. Res. Rev. 2014;34:340–437. doi: 10.1002/med.21290. [DOI] [PubMed] [Google Scholar]
  • 3.Lamberth C., Dinges J. Bioactive Heterocyclic Compound Classes: Pharmaceuticals. Wiley-VCH; Singapore: 2010. pp. 3–16. [Google Scholar]
  • 4.Sharma K., Bhat V.K. On Topological Descriptors of Polycyclic Aromatic Benzenoid Systems. Polycycl. Aromat. Comp. 2023;43:4111–4130. doi: 10.1080/10406638.2022.2086273. [DOI] [Google Scholar]
  • 5.Miao Q., editor. Polycyclic Arenes and Heteroarenes: Synthesis, Properties, and Applications. 1st ed. Wiley-VCH Verlag GmbH & Co., KGaA; Weinheim, Germany: 2016. [Google Scholar]
  • 6.Stępień M., Gońka E., Żyła M., Sprutta N. Heterocyclic Nanographenes and Other Polycyclic Heteroaromatic Compounds: Synthetic Routes, Properties, and Applications. Chem. Rev. 2017;117:3479–3716. doi: 10.1021/acs.chemrev.6b00076. [DOI] [PubMed] [Google Scholar]
  • 7.Ghosh D., Ghosh S., Hajra A. Electrochemical Functionalization of Imidazopyridine and Indazole: An Overview. Adv. Synth. Catal. 2021;363:5047–5071. doi: 10.1002/adsc.202100981. [DOI] [Google Scholar]
  • 8.Shafakat Ali N.A., Dar B., Pradhan V., Farooqui M. Chemistry and Biology of Indoles and Indazoles: A Mini-Review. Mini-Rev. Med. Chem. 2013;13:1792–1800. doi: 10.2174/1389557511313120009. [DOI] [PubMed] [Google Scholar]
  • 9.Gaikwad D.D., Chapolikar A.D., Devkate C.G., Warad K.D., Tayade A.P., Pawar R.P., Domb A.J. Synthesis of Indazole Motifs and Their Medicinal Importance: An Overview. Eur. J. Med. Chem. 2015;90:707–731. doi: 10.1016/j.ejmech.2014.11.029. [DOI] [PubMed] [Google Scholar]
  • 10.Aman W., Lee J., Kim M., Yang S., Jung H., Hah J.-M. Discovery of Highly Selective CRAF Inhibitors, 3-Carboxamido-2H-Indazole-6-Arylamide: In Silico FBLD Design, Synthesis and Evaluation. Bioorg. Med. Chem. Lett. 2016;26:1188–1192. doi: 10.1016/j.bmcl.2016.01.037. [DOI] [PubMed] [Google Scholar]
  • 11.Cheng Y., Li G., Liu Y., Shi Y., Gao G., Wu D., Lan J., You J. Unparalleled Ease of Access to a Library of Biheteroaryl Fluorophores via Oxidative Cross-Coupling Reactions: Discovery of Photostable NIR Probe for Mitochondria. J. Am. Chem. Soc. 2016;138:4730–4738. doi: 10.1021/jacs.5b09241. [DOI] [PubMed] [Google Scholar]
  • 12.Liu J., Qian C., Zhu Y., Cai J., He Y., Li J., Wang T., Zhu H., Li Z., Li W., et al. Design, Synthesis and Evaluate of Novel Dual FGFR1 and HDAC Inhibitors Bearing an Indazole Scaffold. Bioorg. Med. Chem. 2018;26:747–757. doi: 10.1016/j.bmc.2017.12.041. [DOI] [PubMed] [Google Scholar]
  • 13.Guillon J., Grellier P., Labaied M., Sonnet P., Leger J.M., Deprez-Poulain R., Forfar-Bares I., Dallemagne P., Lemaitre N., Pehourcq F., et al. Synthesis, Antimalarial Activity, and Molecular Modeling of New Pyrrolo[1,2-a]quinoxalines, Bispyrrolo-[1,2-a]quinoxalines, Bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and Bispyrrolo[1,2-a]thieno[3,2-e]pyrazines. J. Med. Chem. 2004;47:1997–2009. doi: 10.1021/jm0310840. [DOI] [PubMed] [Google Scholar]
  • 14.Desplat V., Vincenzi M., Lucas R., Moreau S., Savrimoutou S., Pinaud N., Lesbordes J., Peyrilles E., Marchivie M., Routier S., et al. Synthesis and Evaluation of the Cytotoxic Activity of Novel Ethyl 4-[4-(4-substitutedpiperidin-1-yl)]-benzyl-phenylpyrrolo [1,2-a]quinoxaline-carboxylate Derivatives in Myeloid and Lymphoid Leukemia Cell Lines. Eur. J. Med. Chem. 2016;113:214–227. doi: 10.1016/j.ejmech.2016.02.047. [DOI] [PubMed] [Google Scholar]
  • 15.Guillon J., LeBorgne M., Rimbault C., Moreau S., Savrimoutou S., Pinaud N., Baratin S., Marchivie M., Roche S., Bollacke A., et al. Synthesis and Biological Evaluation of Novel Substituted Pyrrolo[1,2-a]quinoxaline Derivatives as Inhibitors of the Human Protein Kinase CK2. Eur. J. Med. Chem. 2013;65:205–222. doi: 10.1016/j.ejmech.2013.04.051. [DOI] [PubMed] [Google Scholar]
  • 16.Jones E.D., Vandegraaff N., Le G., Choi N., Issa W., Macfarlane K., Thienthong N., Winfield L.J., Coates J.A.V., Lu L., et al. Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold. Bioorg. Med. Chem. Lett. 2010;20:5913–5917. doi: 10.1016/j.bmcl.2010.07.079. [DOI] [PubMed] [Google Scholar]
  • 17.Wang L., Mason K.A., Ang K.K., Buchholz T., Valdecanas D., Mathur A., Buser-Doepner C., Toniatti C., Milas L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investig. New Drugs. 2012;30:2113–2120. doi: 10.1007/s10637-011-9770-x. [DOI] [PubMed] [Google Scholar]
  • 18.Bischoff F., Berthelot D., De Cleyn M., Macdonald G., Minne G., Oehlrich D., Pieters S., Surkyn M., Trabanco A.A., Tresadern G., et al. Design and Synthesis of a Novel Series of Bicyclic Heterocycles as Potent γ-Secretase Modulators. J. Med. Chem. 2012;55:9089–9106. doi: 10.1021/jm201710f. [DOI] [PubMed] [Google Scholar]
  • 19.Bridges K.A., Hirai H., Buser C.A., Brooks C., Liu H., Buchholz T.A., Molkentine J.M., Mason K.A., Meyn R.E. MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells. Clin. Cancer Res. 2011;17:5638–5648. doi: 10.1158/1078-0432.CCR-11-0650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jones P., Altamura S., Boueres J., Ferrigno F., Fonsi M., Giomini C., Lamartina S., Monteagudo E., Ontoria J.M., Orsale M.V., et al. Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADPribose)polymerase (PARP) Inhibitor Efcacious in BRCA-1 and -2 Mutant Tumors. J. Med. Chem. 2009;52:7170–7185. doi: 10.1021/jm901188v. [DOI] [PubMed] [Google Scholar]
  • 21.Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., Shumway S.D., Mizuarai S., Hirai H., Maitra A., et al. MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Defcient Pancreatic Cancer Xenografs. Clin. Cancer Res. 2011;17:2799–2806. doi: 10.1158/1078-0432.CCR-10-2580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhu C., Feng C., Yamane M. Pd/Cu Cooperative Catalysis: An Efficient Synthesis of (3-isoindazolyl)allenes via Cross-Coupling of 2-Alkynyl Azobenzenes and Terminal Alkynes. Chem. Commun. 2017;53:2606–2609. doi: 10.1039/C7CC00562H. [DOI] [PubMed] [Google Scholar]
  • 23.Guo C., Li B., Liu H., Zhang X., Zhang X., Fan X. Synthesis of Fused or Spiro Polyheterocyclic Compounds via the Dehydrogenative Annulation Reactions of 2-Arylindazoles with Maleimides. Org. Lett. 2019;21:7189–7193. doi: 10.1021/acs.orglett.9b01889. [DOI] [PubMed] [Google Scholar]
  • 24.Lin W.-C., Yang D.-Y. Visible Light Photoredox Catalysis: Synthesis of Indazolo[2,3-a]quinolines from 2-(2-Nitrophenyl)-1,2,3,4-tetrahydroquinolines. Org. Lett. 2013;15:4862–4865. doi: 10.1021/ol402286d. [DOI] [PubMed] [Google Scholar]
  • 25.Zhou Y., Lei S.-G., Wang L.-S., Ma J.-T., Yu Z.-C., Wu Y.-D., Wu A.-X. I2-Promoted gem-Diarylethene Involved Aza-Diels–Alder Reaction and Wagner–Meerwein Rearrangement: Construction of 2,3,4-Trisubstituted Pyrimido[1,2-b]indazole Skeletons. Org. Lett. 2023;25:3386–3390. doi: 10.1021/acs.orglett.3c00886. [DOI] [PubMed] [Google Scholar]
  • 26.Balwe S.G., Jeong Y.T. An Approach towards the Synthesis of Novel Fused Nitrogen Tricyclic Heterocyclic Scaffolds via GBB reaction. Org. Biomol. Chem. 2018;16:1287–1296. doi: 10.1039/C7OB02933K. [DOI] [PubMed] [Google Scholar]
  • 27.Balwe S.G., Jeong Y.T. One-step Construction of Complex Polyheterocycles via a Sequential Post-GBB Cyclization/Spiro Ring Expansion Triggered by a [1,5]-Hydride Shift. Org. Chem. Front. 2018;5:1628–1632. doi: 10.1039/C8QO00071A. [DOI] [Google Scholar]
  • 28.Xu J., Tan H.-B., Zhang Y.-J., Tang D.-Y., Zhan F., Li H., Chen Z.-Z., Xu Z.-G. Catalyst-Free One-pot Synthesis of Densely Substituted Pyrazolepyrazines as Anti-colorectal Cancer Agents. Sci. Rep. 2020;10:9281. doi: 10.1038/s41598-020-66137-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Russo C., Brunelli F., Tron G.C., Giustiniano M. Isocyanide-Based Multicomponent Reactions Promoted by Visible Light Photoredox Catalysis. Chem. Eur. J. 2023;29:e202203150. doi: 10.1002/chem.202203150. [DOI] [PubMed] [Google Scholar]
  • 30.Meier M.A.R., Hu R., Tang B.Z. Multicomponent Reactions in Polymer Science. Macrmol. Rapid Comm. 2021;42:2100104. doi: 10.1002/marc.202100104. [DOI] [PubMed] [Google Scholar]
  • 31.Cimarelli C. Multicomponent Reactions. Molecules. 2019;24:2372. doi: 10.3390/molecules24132372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Garbarino S., Ravelli D., Protti S., Basso A. Photoinduced Multicomponent Reactions. Angew. Chem. Int. Ed. 2016;55:15476–15484. doi: 10.1002/anie.201605288. [DOI] [PubMed] [Google Scholar]
  • 33.Cioc R.C., Ruijter E., Orru R.V.A. Multi-component Reactions: Advanced Tools for Sustainable Organic Synthesis. Green Chem. 2014;16:2958–2975. doi: 10.1039/C4GC00013G. [DOI] [Google Scholar]
  • 34.Marcaccini S., Torroba T. The Use of the Ugi Four-Component Condensation. Nat. Protoc. 2007;2:632–639. doi: 10.1038/nprot.2007.71. [DOI] [PubMed] [Google Scholar]
  • 35.Sharma U.K., Sharma N., Vachhani D.D., Van der Eycken E.V. Metal-mediated Post-Ugi Transformations for the Construction of Diverse Heterocyclic Scaffolds. Chem. Soc. Rev. 2015;44:1836–1860. doi: 10.1039/C4CS00253A. [DOI] [PubMed] [Google Scholar]
  • 36.Xu Z.-G., Li S.-Q., Meng J.-P., Tang D.-Y., He L.-J., Lei J., Lin H.-K., Li H.-Y., Chen Z.-Z. Functionalized Spiroindolines with Anticancer Activity through a Metal-Free Post-Ugi Diastereoselective One-Pot Cascade Reaction. Chem. Eur. J. 2018;24:6732–6736. doi: 10.1002/chem.201801081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tang X., Song L., Van der Eycken E.V. Post-Ugi Cyclizations towards Polycyclic N-Heterocycles. Chem. Rec. 2023;23:e202300095. doi: 10.1002/tcr.202300095. [DOI] [PubMed] [Google Scholar]
  • 38.Fouad M.A., Abdel-Hamid H., Ayoup M.S. Two Decades of Recent Advances of Ugi Reactions: Synthetic and Pharmaceutical applications. RSC Adv. 2020;10:42644–42681. doi: 10.1039/D0RA07501A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kumar V., Saxena A., Patra R., Ray D., Li H., Saha B. Synthesis of Fused Polycyclic β-carboline Derivatives Using Ugi-4CR Followed by Cascade Cyclization. Mol. Divers. 2023;27:951–957. doi: 10.1007/s11030-022-10451-3. [DOI] [PubMed] [Google Scholar]
  • 40.Lei J., Meng J.-P., Tang D.-Y., Frett B., Chen Z.-Z., Xu Z.-G. Recent Ad vances in the Development of Polycyclic Skeletons via Ugi Reaction Cascades. Mol. Divers. 2018;22:503–516. doi: 10.1007/s11030-017-9811-2. [DOI] [PubMed] [Google Scholar]
  • 41.Li Z., Song L., Meervelt L.V., Tian G., Van der Eycken E.V. Cationic Gold (I)-Catalyzed Cascade Bicyclizations for Divergent Synthesis of (Spiro) Polyheterocycles. ACS Catal. 2018;8:6388–6393. doi: 10.1021/acscatal.8b01789. [DOI] [Google Scholar]
  • 42.Liu C., Song L., Van Meervelt L., Peshkov V.A., Li Z., Van der Eycken E.V. Palladium-Catalyzed Arylative Dearomatization and Subsequent Aromatization/Dearomatization/aza-Michael Addition: Access to Zephycarinatine and Zephygranditine Skeletons. Org. Lett. 2021;23:5065–5070. doi: 10.1021/acs.orglett.1c01590. [DOI] [PubMed] [Google Scholar]
  • 43.Li X., Zarganes-Tzitzikas T., Kurpiewska K., Dömling A. Amenamevir by Ugi-4CR. Green Chem. 2023;25:1322–1325. doi: 10.1039/D2GC04869H. [DOI] [Google Scholar]
  • 44.Li Y., Xu J., He L.-J., Luo Y.-F., Meng J.-P., Tang D.-Y., Li H., Chen Z.-Z., Xu Z.-G. Dieckmann Condensation of Ugi N-Acylamino Amide Product: Facile Access to Functionalized 2,2-Disubstituted Indolin-3-ones. J. Org. Chem. 2022;87:823–834. doi: 10.1021/acs.joc.1c02501. [DOI] [PubMed] [Google Scholar]
  • 45.Li Y., Huang J.-H., Wang J.-L., Song G.-T., Tang D.-Y., Yao F., Lin H., Yan W., Li H., Xu Z.-G., et al. Diversity-Oriented Synthesis of Imidazo-Dipyridines with Anticancer Activity via the Groebke-Blackburn-Bienaymé and TBAB-Mediated Cascade Reaction in One Pot. J. Org. Chem. 2019;84:12632–12638. doi: 10.1021/acs.joc.9b01385. [DOI] [PubMed] [Google Scholar]
  • 46.Yang D.-L., Qin H.-X., Zhang N.-N., Zhang Y.-J., Huang J.-H., Hu C.-S., Zhang X.-X., Li Y., He L.-J. Pyrrolyldihydropyrazino [1,2- a]indoletrione Analogue Microtubule Inhibitor Induces Cell-Cycle Arrest and Apoptosis in Colorectal Cancer Cells. Molecules. 2023;28:1948. doi: 10.3390/molecules28041948. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (2.4MB, zip)

Data Availability Statement

All the required data are reported in the manuscript and Supplementary Materials.

Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES